Holen Sie sich die Stockscreener-App
561.55
0.90%
4.995
Handel nachbörslich:
562.00
0.45
+0.08%
Schlusskurs vom Vortag:
$556.55
Offen:
$557.08
24-Stunden-Volumen:
1.10M
Relative Volume:
0.92
Marktkapitalisierung:
$58.50B
Einnahmen:
$14.21B
Nettoeinkommen (Verlust:
$4.46B
KGV:
14.15
EPS:
39.68
Netto-Cashflow:
$3.56B
1W Leistung:
+1.16%
1M Leistung:
-1.09%
6M Leistung:
-16.72%
1J Leistung:
-51.52%
1-Tages-Spanne:
$552.00
$565.50
1-Wochen-Bereich:
$544.16
$572.58
52-Wochen-Spanne:
$476.49
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Fund Update: DODGE & COX added 1,502,198 shares of REGENERON PHARMACEUTICALS (REGN) to their portfolio - Quiver Quantitative
Citizens Financial Group Inc. RI Sells 465 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game-Changer? - TipRanks
Cantor Fitzgerald maintains Regeneron stock rating despite mixed update By Investing.com - Investing.com Canada
Here’s Why You Should Consider Buying Regeneron Pharma (REGN)’s Shares - Insider Monkey
Lead Plaintiff Appointed in Regeneron Pharmaceuticals Class Action - TradingView
Charles Schwab Investment Management Inc. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Mizuho Securities USA LLC - MarketBeat
National Bank of Canada FI Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Deutsche Bank AG Has $344.45 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Forsta AP Fonden Sells 1,300 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Maryland State Retirement & Pension System Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Townsquare Capital LLC Purchases 2,854 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Swiss National Bank - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - FinancialContent
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00 - MarketBeat
Sanofi halts China sales of cholesterol drug Praluent (SNY) - Seeking Alpha
Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810 - MSN
Knott David M Jr Takes $1.27 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Invesco Ltd. Has $539.57 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
AIA Group Ltd Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sanofi stops supply of high cholesterol drug to China due to limited availability - The Mighty 790 KFGO
Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners - MSN
Nuveen LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Cary Street Partners Financial LLC Sells 959 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
ASR Vermogensbeheer N.V. Buys Shares of 9,485 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Headlands Technologies LLC Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity (NASDAQ:REGN) - Seeking Alpha
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point - Stocktwits
Truist Securities lowers Regeneron Pharma stock price target on Eylea concerns - Investing.com
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings - Benzinga
Follicular Lymphoma Market Trends Point to Steady Growth Ahead - openPR.com
Follicular Lymphoma Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Roche, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly - Barchart.com
Truist Securities Adjusts Regeneron Pharmaceuticals Price Target to $812 From $940, Maintains Buy Rating - MarketScreener
Zymeworks Strengthens Board with Healthcare Veterans as Key Trial Results Near - Stock Titan
Aigen Investment Management LP Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Entropy Technologies LP - MarketBeat
What Regeneron Pharmaceuticals (REGN)'s Strong Q2 Results and Dupixent FDA Approval Mean For Shareholders - simplywall.st
Cornerstone Advisors LLC Has $3.87 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform - MSN
New Age Alpha Advisors LLC Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
11 Best GLP-1 and Weight Loss Stocks to Invest in - Insider Monkey
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):